A Case of Immune-Related Aseptic Meningitis during Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma

Introduction: Immune checkpoint inhibitors are sometimes associated with immune-related adverse events during or after treatment. Among these, aseptic meningitis is a rare and serious complication. We report the first case of atezolizumab-induced aseptic meningitis, which occurred during treatment f...

Full description

Bibliographic Details
Published in:	Case Reports in Gastroenterology
Main Authors:	Hiroki Kawanaka, Kazuto Tajiri, Nozomu Muraishi, Aiko Murayama, Takamasa Nukui, Ichiro Yasuda
Format:	Article
Language:	English
Published:	Karger Publishers 2024-01-01
Subjects:	atezolizumab bevacizumab immure-related adverse event aseptic meningitis
Online Access:	https://beta.karger.com/Article/FullText/535476

Similar Items

Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis
by: Qingzi Yan, et al.
Published: (2025-01-01)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
by: Kazuhiro Nouso, et al.
Published: (2023-09-01)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023-08-01)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
by: Tetsu Tomonari, et al.
Published: (2023-02-01)

Aseptic Meningitis Following Spinal Anesthesia: A Diagnostic Dilemma
by: Meena Kumari, et al.
Published: (2025-01-01)

Amoxicillin-induced aseptic meningitis: clinical features, diagnosis and management
by: Zhiqiang Fan, et al.
Published: (2023-08-01)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
by: Sri Harsha Tella, et al.
Published: (2022-06-01)

Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment
by: F. Rossari, et al.
Published: (2025-06-01)

Letter regarding “Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab”
by: Sun Hyun Bae, et al.
Published: (2023-09-01)

CNS Complications of Aseptic Meningitis in Infants
by: J Gordon Millichap
Published: (1993-10-01)

Benign Recurrent Aseptic Meningitis (Mollaret’s Meningitis) in an Elderly Male: A Case Report
by: Swati Chand, et al.
Published: (2021-09-01)

Clinical Characteristics, Diagnosis, and Management of Aseptic Meningitis Induced by Trimethoprim-Sulfamethoxazole
by: Fan Z, et al.
Published: (2023-09-01)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023-09-01)

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)

Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
by: Young Shin Song, et al.
Published: (2023-05-01)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
by: Tomoyuki Satake, et al.
Published: (2023-07-01)

Incidence and Risk of Hypertension in Cancer Patients Treated With Atezolizumab and Bevacizumab: A Systematic Review and Meta-Analysis
by: Linhan Jiang, et al.
Published: (2021-10-01)

Efficacy of Atezolizumab Plus Bevacizumab–Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma
by: Etsuko Moriyama, et al.
Published: (2024-09-01)

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
by: Young Eun Chon, et al.
Published: (2024-07-01)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Toshifumi Tada, et al.
Published: (2023-04-01)

Neurobrucellosis manifested by recurrent aseptic meningitis: A case report
by: Reza Razaghi, et al.
Published: (2025-01-01)

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
by: Sun Young Yim, et al.
Published: (2024-10-01)

Familial Mediterranean fever in a patient with two surgical procedures of abdomen and aseptic meningitis
by: Seyyed Gholam Reza Mortazavimoghaddam, et al.
Published: (2012-08-01)

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
by: Yasuto Takeuchi, et al.
Published: (2023-09-01)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023-03-01)

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
by: Margherita Rimini, et al.
Published: (2024-08-01)

Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma
by: Shaobo Zhang, et al.
Published: (2025-05-01)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
by: Hannah Yang, et al.
Published: (2023-04-01)

Application effect of two modalities for placing lumbar drain catheters in patients with postcraniotomy aseptic meningitis
by: Ji Zhang, et al.
Published: (2021-03-01)

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
by: Sae Yumita, et al.
Published: (2023-03-01)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
by: Ryosuke Tsunemitsu, et al.
Published: (2023-06-01)

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
by: Masatoshi Kudo
Published: (2021-02-01)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
by: Toshifumi Tada, et al.
Published: (2022-10-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
by: Zili Hu, et al.
Published: (2024-11-01)

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
by: Shen X, et al.
Published: (2024-10-01)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
by: Yasuhito Mitsuyama, MD, et al.
Published: (2023-09-01)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
by: Yong Tae Kim, et al.
Published: (2023-03-01)

New in neuroprotective therapy for children with aseptic meningitis.
by: M. V. Ivanova, et al.
Published: (2014-09-01)

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
by: Masatoshi Kudo, et al.
Published: (2023-11-01)

Investigating the etiologic agents of aseptic meningitis outbreak in Iranian children
by: Abdolkarim Ghadimi Moghadam, et al.
Published: (2020-01-01)